


I hereby certify that this paper is being
Facsimile transmitted to the Patent and
Trademark Office on February 28, 2002

AMENDMENT UNDER 37 CFR §1.111
Examining Group 1625
Patent Application
Docket No. GJE-136D1
Serial No. 09/928,139


Doran R. Pace, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ceila Chang
Art Unit : 1625
Applicants : Marianne Langston, Hooshang Shahriari Zavareh
Serial No. : 09/928,139
Filed : August 10, 2001
Conf. No. : 6929
For : Manufacture of Single Isomer Methylphenidate

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT UNDER 37 CFR §1.111

Sir:


A Petition and Fee for a two-month Extension of Time through and including February 28, 2002, accompanies this Amendment.

In response to the Office Action dated September 28, 2001, please amend the above-identified patent application as follows:

In the Claims

Please substitute the following claims:

Claim 1 (amended):


1. A process for obtaining single enantiomer *d-threo*-methylphenidate or *l-threo*-methylphenidate, which comprises resolution of a mixture of the *d-threo*-methylphenidate and *l-threo*-methylphenidate enantiomers; racemisation of the unwanted enantiomer, to give a mixture of

S:\SH-RESP\GJE-136D1.doc/DNB/sl